Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07052266 · ClinicalTrials.gov registry record · NA
Trial of Combined Obstetric Carrier Screening and Hereditary Cancer Screening
A NA study of Hereditary Cancer Syndromes, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- NA
- Development phase
- 550
- Enrollment target
- 5
- Study locations
NCT07052266: Recruiting NA study of Hereditary Cancer Syndromes, sponsored by Weill Medical College of Cornell University.
NCT07052266 is a NA study of Hereditary Cancer Syndromes that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 550 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (61% lower). The trial reports 5 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07052266, a NA study of Hereditary Cancer Syndromes, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- NA
- Development phase
- 550 participants
- Enrollment target
- 5
- Study locations
Study Summary
The investigators hypothesize that pregnancy and preconception care may be a feasible and effective time to offer inherited cancer risk screening. This study will assess interest in cancer genetic testing among patients receiving routine prenatal or preconception/fertility care. The goal is to evaluate the acceptability of BRCA1/2 testing when offered alongside standard prenatal genetic screening. The study will also explore whether universal screening in this population could support early cancer prevention and be cost-effective, especially among underserved populations.
Primary Outcome
Percentage of enrolled participants who successfully complete both HCS and OCS during the study period. Completion is defined as having documented results for both screenings
Conditions Studied
Interventions
- GENETIC MyRisk Hereditary Cancer Test
Study Locations (5)
New York
- Reproductive Medicine - Brooklyn
- NewYork-Presbyterian Weill Cornell Medicine - Brooklyn
- Reproductive Medicine - New York
- Weill Cornell Medicine - New York
- NewYork-Presbyterian Weill Cornell Medicine Queens - Queens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2025-09-02 |
| Est. Completion | 2028-12 |
| Phase | NA |
What NCT07052266 shows while recruiting
NCT07052266 is an interventional study that assigns participants to a tested intervention. The registered 550 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Hereditary Cancer Syndromes appearing as the primary indexed condition, and to 1 intervention - of which MyRisk Hereditary Cancer Test is the first listed.
NCT07052266 lists 5 locations in 1 state (New York).
Frequently Asked Questions
What is clinical trial NCT07052266 about?
NCT07052266 is a clinical study titled "Trial of Combined Obstetric Carrier Screening and Hereditary Cancer Screening". The investigators hypothesize that pregnancy and preconception care may be a feasible and effective time to offer inherited cancer risk screening. This study will assess interest in cancer genetic testing among patients receiving routine prenatal or preconception/fertility care. The goal is to evalu...
What is the current status of trial NCT07052266?
This trial is currently recruiting. It is a NA study. The enrollment target is 550 participants. The study started on 2025-09-02. Estimated completion is 2028-12.
What conditions does trial NCT07052266 study?
This clinical trial studies the following conditions: Hereditary Cancer Syndromes.
What interventions are being tested in trial NCT07052266?
The interventions under investigation include: MyRisk Hereditary Cancer Test (GENETIC).
Who is sponsoring clinical trial NCT07052266?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07052266 being conducted?
This trial has 5 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Cancer Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07052266's enrollment target sits among peer trials
550 184th of 2000 higher than 1,815 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
- NCT02995252 · 550 participants
The HOPE Study: Characterizing Patients With Hepatitis B and C
- NCT03474913 · 550 participants
Upright MRI for Prostate Cancer Screening
- NCT04761120 · 550 participants
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI